Pharmacokinetic determinants of the clinical effects of benzodiazepine agonist hypnotics

GABA and Sleep: Molecular, Functional and Clinical Aspects

Volumn 9783034602266, Issue , 2010, Pages 95-118

  Greenblatt, David J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 82155162967     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-0346-0226-6_4     Document Type: Chapter

References (162)

1. Kupfer DJ, Reynolds CF (1997) Management of insomnia. N Engl J Med 336:341-346
2. Thase ME (2005) Correlates and consequences of chronic insomnia. Gen Hosp Psychiatry 27:100-112
3. Sateia MJ, Nowell PD (2004) Insomnia. Lancet 364:1959-1973
4. Simon GE, Von Korff M (1997) Prevalence, burden, and treatment of insomnia in primary care. Am J Psychiatry 154:1417-1423
5. Drake CL, Roehrs T, Roth T (2003) Insomnia causes, consequences, and therapeutics: an overview. Depress Anxiety 18:163-176
6. Sharpley A (1996) Impact of daytime sleepiness underrated. Lancet 348:71
7. Dement WC, Mitler MM (1993) It's time to wake up to the importance of sleep disorders. JAMA 269:1548-1550
8. Sagberg F (1999) Road accidents caused by drivers falling asleep. Accid Anal Prev 31:639-649
9. Powell NB, Schechtman KB, Riley RW, Li K, Troell R, Guilleminault C (2001) The road to danger: the comparative risks of driving while sleepy. Laryngoscope 111:887-893
10. Connor J, Norton R, Ameratunga S, Robinson E, Civil I, Dunn R, Bailey J, Jackson R (2002) Driver sleepiness and risk of serious injury to car occupants: population based case control study. BMJ 324:1125
11. Leger D (1994) The cost of sleep-related accidents: a report for the National Commission on Sleep Disorders Research. Sleep 17:84-93
12. Garbarino S, Nobili L, Beelke M, De Carli F, Ferrillo F (2001) The contributing role of sleepiness in highway vehicle accidents. Sleep 24:203-206
13. Vermeeren A (2004) Residual effects of hypnotics: epidemiology and clinical implications. CNS Drugs 18:297-328
14. Verster JC, Veldhuijzen DS, Patat A, Olivier B, Volkerts ER (2006) Hypnotics and driving safety: meta-analyses of randomized controlled trials applying the on-the-road driving test. Curr Drug Saf 1:63-71
15. Verster JC, Veldhuijzen DS, Volkerts ER (2004) Residual effects of sleep medication on driving ability. Sleep Med Rev 8:309-325
16. Bramness JG, Skurtveit S, Morland J (2002) Clinical impairment of benzodiazepines-relation between benzodiazepine concentrations and impairment in apprehended drivers. Drug Alcohol Depend 68:131-141
17. Kelly E, Darke S, Ross J (2004) A review of drug use and driving: epidemiology, impairment, risk factors and risk perceptions. Drug Alcohol Rev 23:319-344
18. Oster G, Huse DM, Adams SF, Imbimbo J, Russell MW (1990) Benzodiazepine tranquilizers and the risk of accidental injury. Am J Public Health 80:1467-1470
19. Movig KL, Mathijssen MP, Nagel PH, van Egmond T, de Gier JJ, Leufkens HG, Egberts AC (2004) Psychoactive substance use and the risk of motor vehicle accidents. Accid Anal Prev 36:631-636
20. Barbone F, McMahon AD, Davey PG, Morris AD, Reid IC, McDevitt DG, MacDonald TM (1998) Association of road-traffic accidents with benzodiazepine use. Lancet 352:1331-1336
21. Neutel I (1998) Benzodiazepine-related traffic accidents in young and elderly drivers. Hum Psychopharmacol Clin Exp 13:S115-S123
22. 'Benzodiazepine/Driving' Collaborative Group (1993) Are benzodiazepines a risk factor for road accidents? Drug Alcohol Depend 33:19-22
23. Verster JC, Mets MA (2009) Psychoactive medication and traffic safety. Int J Environ Res Public Health 6:1041-1054
24. O'Neill D (1998) Benzodiazepines and driver safety. Lancet 352:1324-1325
25. Philip P, Sagaspe P, Taillard J, Valtat C, Moore N, Akerstedt T, Charles A, Bioulac B (2005) Fatigue, sleepiness, and performance in simulated versus real driving conditions. Sleep 28:1511-1516
26. Greenblatt DJ, Divoll M, Abernethy DR, Shader RI (1982) Benzodiazepine hypnotics: kinetic and therapeutic options. Sleep 5(Suppl 1):S18-S27
27. Greenblatt DJ, Abernethy DR, Divoll M, Harmatz JS, Shader RI (1983) Pharmacokinetic properties of benzodiazepine hypnotics. J Clin Psychopharmacol 3:129-132
28. Greenblatt DJ, Divoll M, Abernethy DR, Ochs HR, Shader RI (1983) Benzodiazepine kinetics: implications for therapeutics and pharmacogeriatrics. Drug Metab Rev 14:251-292
29. Greenblatt DJ, Shader RI, Abernethy DR (1983) Current status of benzodiazepines. N Engl J Med 309(354-358):410-416
30. Greenblatt DJ, Shader RI (1987) Pharmacokinetics of antianxiety agents. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 1377-1384
31. Greenblatt DJ, Harmatz JS, Engelhardt N, Shader RI (1989) Pharmacokinetic determinants of dynamic differences among three benzodiazepine hypnotics: flurazepam, temazepam, and triazolam. Arch Gen Psychiatry 46:326-332
32. Greenblatt DJ (1991) Benzodiazepine hypnotics: sorting the pharmacokinetic facts. J Clin Psychiatry 52:4-10, Sept Suppl
33. Greenblatt DJ (1992) Pharmacology of benzodiazepine hypnotics. J Clin Psychiatry 53(6 Suppl):7-13
34. Greenblatt DJ (2008) Sleep and geriatric psychopharmacology. In: Pandi-Perumal SR, Verster JC, Monti JM, Lader MH, Langer SZ (eds) Sleep disorders: diagnosis and therapeutics. Informa Healthcare, London, pp 163-173
35. Greenblatt DJ, Shader RI (1974) Benzodiazepines in clinical practice. Raven Press, New York, p 305
36. Greenblatt DJ, Miller RR (1979) Hypnotics. In: Miller RR, Greenblatt DJ (eds) Handbook of drug therapy. Elsevier, New York, pp 507-519
37. Greenblatt DJ, Shader RI (1972) The clinical choice of sedative-hypnotics. Ann Intern Med 77:91-100
38. Matthew H, Proudfoot AT, Aitken RC, Raeburn JA, Wright N (1969) Nitrazepam-a safe hypnotic. Br Med J 3:23-25
39. Barraclough BM (1974) Are there safer hypnotics than barbiturates? Lancet 1:57-58
40. Koch-Weser J, Greenblatt DJ (1974) The archaic barbiturate hypnotics. N Engl J Med 291:790-791
41. Greenblatt DJ, Allen MD, Noel BJ, Shader RI (1977) Acute overdosage with benzodiazepine derivatives. Clin Pharmacol Ther 21:497-514
42. A receptor subtypes. Adv Pharmacol 54:231-263
43. Greenblatt DJ, Shader RI, Koch-Weser J (1975) Flurazepam hydrochloride. Clin Pharmacol Ther 17:1-14
44. Greenblatt DJ, Shader RI, Koch-Weser J (1975) Flurazepam hydrochloride, a benzodiazepine hypnotic. Ann Intern Med 83:237-241
45. Blackwell B (1973) Psychotropic drugs in use today. The role of diazepam in medical practice. JAMA 225:1637-1641
46. Wysowski DK, Baum C (1991) Outpatient use of prescription sedative-hypnotic drugs in the United States, 1970 through 1989. Arch Intern Med 151:1779-1783
47. Greenblatt DJ, Shader RI (1974) Drug therapy. Benzodiazepines. N Engl J Med 291(1011-1015):1239-1243
48. Tyrer P (1974) The benzodiazepine bonanza. Lancet 2:709-710
49. Editorial (1973) Profits from drugs. Br Med J 2:132
50. Editorial (1973) Unreasonable profit. Lancet 1:867
51. Mellinger GD, Balter MB, Uhlenhuth EH (1985) Insomnia and its treatment. Prevalence and correlates. Arch Gen Psychiatry 42:225-232
52. Woods JH, Katz JL, Winger G (1987) Abuse liability of benzodiazepines. Pharmacol Rev 39:251-413
53. Woods JH, Katz JL, Winger G (1988) Use and abuse of benzodiazepines. Issues relevant to prescribing. JAMA 260:3476-3480
54. Woods JH, Katz JL, Winger G (1992) Benzodiazepines: use, abuse, and consequences. Pharmacol Rev 44:151-347
55. Woods JH, Winger G (1995) Current benzodiazepine issues. Psychopharmacology (Berl) 118:107-115, Discussion 118:120-101
56. Lasagna L (1980) The Halcion story: trial by media. Lancet 1:815-816
57. Jonas JM (1992) Idiosyncratic side effects of short half-life benzodiazepine hypnotics: fact or fancy? Hum Psychopharmacol 7:205-216
58. Institute of Medicine (1997) Halcion: an independent assessment of saftey and efficacy data. National Academy Press, Washington DC
59. Drover DR (2004) Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin Pharmacokinet 43:227-238
60. Rush CR (1998) Behavioral pharmacology of zolpidem relative to benzodiazepines: a review. Pharmacol Biochem Behav 61:253-269
61. Langtry HD, Benfield P (1990) Zolpidem: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 40:291-313
62. Harrison TS, Keating GM (2005) Zolpidem: a review of its use in the management of insomnia. CNS Drugs 19:65-89
63. Hoehns JD, Perry PJ (1993) Zolpidem: a nonbenzodiazepine hypnotic for treatment of insomnia. Clin Pharm 12:814-828
64. Holm KJ, Goa KL (2000) Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs 59:865-889
65. Darcourt G, Pringuey D, Sallière D, Lavoisy J (1999) The safety and tolerability of zolpidem: an update. J Psychopharmacol 13:81-93
66. A receptor subtypes. Pharmacol Rev 47:181-234
67. A receptor subtypes: from pharmacology to molecular biology. FASEB J 5:2916-2923
68. A receptor subtypes: dissecting their pharmacological functions. Trends Pharmacol Sci 22:188-194
69. A receptor subtypes: any clues to the mechanism of benzodiazepine dependence? Curr Opin Pharmacol 5:47-52
70. A receptor subtype selectivity to abuse liability and dependence potential of pharmacological treatments for anxiety and sleep disorders. CNS Spectr 10:31-39
71. A receptors. Trends Pharmacol Sci 18:425-429
72. A receptors: properties and trafficking. Crit Rev Biochem Mol Biol 42:3-14
73. A receptor diversity and pharmacology. Cell Tissue Res 326:505-516
74. A-receptor subtypes: clinical efficacy and selectivity of benzodiazepine site ligands. Ann Med 29:275-282
75. A receptor modulators as hypnotics. J Psychopharmacol (Online first)
76. Sanna E, Busonero F, Talani G, Carta M, Massa F, Peis M, Maciocco E, Biggio G (2002) Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA (A) receptor subtypes. Eur J Pharmacol 451:103-110
77. Goa KL, Heel RC (1986) Zopiclone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic. Drugs 32:48-65
78. Melton ST, Wood JM, Kirkwood CK (2005) Eszopiclone for insomnia. Ann Pharmacother 39:1659-1666
79. Najib J (2006) Eszopiclone, a nonbenzodiazepine sedative-hypnotic agent for the treatment of transient and chronic insomnia. Clin Ther 28:491-516
80. Patat A, Paty I, Hindmarch I (2001) Pharmacodynamic profile of zaleplon, a new nonbenzodiazepine hypnotic agent. Hum Psychopharmacol 16:369-392
81. Barbera J, Shapiro C (2005) Benefit-risk assessment of zaleplon in the treatment of insomnia. Drug Saf 28:301-318
82. Dooley M, Plosker GL (2000) Zaleplon: a review of its use in the treatment of insomnia. Drugs 60:413-445
83. Hurst M, Noble S (1999) Zaleplon. CNS Drugs 11:387-392
84. Greenblatt DJ, Sethy VH (1990) Benzodiazepine concentrations in brain directly reflect receptor occupancy: studies of diazepam, lorazepam, and oxazepam. Psychopharmacology 102:373-378
85. Cleton A, Mazee D, Voskuyl RA, Danhof M (1999) Rate of change of blood concentrations is a major determinant of the pharmacodynamics of midazolam in rats. Br J Pharmacol 127:227-235
86. Mandema JW, Tukker E, Danhof M (1991) Pharmacokinetic-pharmacodynamic modelling of the EEG effects of midazolam in individual rats: influence of rate and route of administration. Br J Pharmacol 102:663-668
87. Mandema JW, Kuck MT, Danhof M (1992) In vivo modeling of the pharmacodynamic interaction between benzodiazepines which differ in intrinsic efficacy. J Pharmacol Exp Ther 261:56-61
88. Miller LG, Greenblatt DJ, Paul SM, Shader RI (1987) Benzodiazepine receptor occupancy in vivo: correlation with brain concentrations and pharmacodynamic actions. J Pharmacol Exp Ther 240:516-522
89. Greenblatt DJ, Ehrenberg BL, Gunderman J, Scavone JM, Tai NT, Harmatz JS, Shader RI (1989) Kinetic and dynamic study of intravenous lorazepam: comparison with intravenous diazepam. J Pharmacol Exp Ther 250:134-140
90. Mandema JW, Danhof M (1992) Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs. Clin Pharmacokinet 23:191-215
91. Laurijssens BE, Greenblatt DJ (1996) Pharmacokinetic-pharmacodynamic relationships for benzodiazepines. Clin Pharmacokinet 30:52-76
92. Greenblatt DJ, Koch-Weser J (1975) Clinical pharmacokinetics. N Engl J Med 293(702-705):964-970
93. Mitler MM, Seidel WF, van den Hoed J, Greenblatt DJ, Dement WC (1984) Comparative hypnotic effects of flurazepam, triazolam, and placebo: a long-term simultaneous nighttime and daytime study. J Clin Psychopharmacol 4:2-13
94. Bliwise D, Seidel W, Greenblatt DJ, Dement W (1984) Nighttime and daytime efficacy of flurazepam and oxazepam in chronic insomnia. Am J Psychiatry 141:191-195
95. Bliwise D, Seidel W, Karacan I, Mitler M, Roth T, Zorick F, Dement W (1983) Daytime sleepiness as a criterion in hypnotic medication trials: comparison of triazolam and flurazepam. Sleep 6:156-163
96. Carskadon MA, Seidel WF, Greenblatt DJ, Dement WC (1982) Daytime carryover of triazolam and flurazepam in elderly insomniacs. Sleep 5:361-371
97. Mamelak M, Csima A, Price V (1984) A comparative 25-night sleep laboratory study on the effects of quazepam and triazolam on chronic insomniacs. J Clin Pharmacol 24:65-75
98. Vogel GW, Barker K, Gibbons P, Thurmond A (1976) A comparison of the effects of flurazepam 30 mg and triazolam 0.5 mg on the sleep of insomniacs. Psychopharmacology (Berl) 47:81-86
99. Garland WA, Miwa BJ, Dairman W, Kappell B, Chiueh MC, Divoll M, Greenblatt DJ (1983) Identification of 7-chloro-5-(2'-fluorophenyl)-2, 3-dihydro-2-oxo-1H-1, 4-benzodiazepine-1-acetaldehyde, a new metabolite of flurazepam in man. Drug Metab Dispos 11:70-72
100. Schwartz MA, Postma E (1970) Metabolism of flurazepam, a benzodiazepine, in man and dog. J Pharm Sci 59:1800-1806
101. Kaplan SA, de Silva JA, Jack ML, Alexander K, Strojny N, Weinfeld RE, Puglisi CV, Weissman L (1973) Blood level profile in man following chronic oral administration of flurazepam hydrochloride. J Pharm Sci 62:1932-1935
102. Miller LG, Greenblatt DJ, Abernethy DR, Friedman H, Luu MD, Paul SM, Shader RI (1988) Kinetics, brain uptake, and receptor binding characteristics of flurazepam and its metabolites. Psychopharmacology 94:386-391
103. Greenblatt DJ, Divoll M, Harmatz JS, MacLaughlin DS, Shader RI (1981) Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs. Clin Pharmacol Ther 30:475-486
104. Greenblatt DJ, Allen MD, Shader RI (1977) Toxicity of high-dose flurazepam in the elderly. Clin Pharmacol Ther 21:355-361
105. Ankier SI, Goa KL (1988) Quazepam. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in insomnia. Drugs 35:42-62
106. Kales A (1990) Quazepam: hypnotic efficacy and side effects. Pharmacotherapy 10:1-10, Discussion 10-12
107. Zampaglione N, Hilbert JM, Ning J, Chung M, Gural R, Symchowicz S (1985) Disposition and metabolic fate of 14C-quazepam in man. Drug Metab Dispos 13:25-29
108. Chung M, Hilbert JM, Gural RP, Radwanski E, Symchowicz S, Zampaglione N (1984) Multiple-dose quazepam kinetics. Clin Pharmacol Ther 35:520-524
109. Hilbert JM, Chung M, Radwanski E, Gural R, Symchowicz S, Zampaglione N (1984) Quazepam kinetics in the elderly. Clin Pharmacol Ther 36:566-569
110. Hilbert JM, Chung M, Maier G, Gural R, Symchowicz S, Zampaglione N (1984) Effect of sleep on quazepam kinetics. Clin Pharmacol Ther 36:99-104
111. Kangas L, Breimer DD (1981) Clinical pharmacokinetics of nitrazepam. Clin Pharmacokinet 6:346-366
112. Jochemsen R, Hogendoorn JJ, Dingemanse J, Hermans J, Boeijinga JK, Breimer DD (1982) Pharmacokinetics and bioavailability of intravenous, oral, and rectal nitrazepam in humans. J Pharmacokinet Biopharm 10:231-245
113. Jochemsen R, van der Graaf M, Boejinga J, Breimer D (1982) Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. Br J Clin Pharmacol 13:319-324
114. Greenblatt DJ, Abernethy DR, Locniskar A, Ochs HR, Harmatz JS, Shader RI (1985) Age, sex, and nitrazepam kinetics: relation to antipyrine disposition. Clin Pharmacol Ther 38:697-703
115. Greenblatt DJ, Allen MD (1978) Toxicity of nitrazepam in the elderly: a report from the Boston Collaborative Drug Surveillance Program. Br J Clin Pharmacol 5:407-413
116. Locniskar A, Greenblatt DJ (1990) Oxidative versus conjugative biotransformation of temazepam. Biopharm Drug Dispos 11:499-506
117. Müller FO, van Dyk M, Hundt HK, Joubert AL, Luus HG, Groenewoud G, Dunbar GC (1987) Pharmacokinetics of temazepam after day-time and night-time oral administration. Eur J Clin Pharmacol 33:211-214
118. Ochs HR, Greenblatt DJ, Heuer H (1984) Is temazepam an accumulating hypnotic? J Clin Pharmacol 24:58-64
119. Schwarz HJ (1979) Pharmacokinetics and metabolism of temazepam in man and several animal species. Br J Clin Pharmacol 8:23S-29S
120. Ochs HR, Greenblatt DJ, Verburg-Ochs B, Matlis R (1986) Temazepam clearance unaltered in cirrhosis. Am J Gastroenterol 81:80-84
121. Divoll M, Greenblatt DJ, Harmatz JS, Shader RI (1981) Effect of age and gender on disposition of temazepam. J Pharm Sci 70:1104-1107
122. Greenblatt DJ, Abernethy DR, Divoll M, Locniskar A, Harmatz JS, Shader RI (1984) Noninteraction of temazepam and cimetidine. J Pharm Sci 73:399-401
123. Ahonen J, Olkkola KT, Neuvonen PJ (1996) Lack of effect of antimycotic itraconazole on the pharmacokinetics or pharmacodynamics of temazepam. Ther Drug Monit 18:124-127
124. Luurila H, Olkkola KT, Neuvonen PJ (1994) Lack of interaction of erythromycin with temazepam. Ther Drug Monit 16:548-551
125. Friedman H, Greenblatt DJ, Burstein ES, Harmatz JS, Shader RI (1986) Population study of triazolam pharmacokinetics. Br J Clin Pharmacol 22:639-642
126. Greenblatt DJ, Harmatz JS, Zinny MA, Shader RI (1987) Effect of gradual withdrawal on the rebound sleep disorder after discontinuation of triazolam. N Engl J Med 317:722-728
127. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE, Shader RI (1996) Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 276:370-379
128. Greenblatt DJ, He P, von Moltke LL, Court MH (2008) The CYP3 family. In: Ioannides C (ed) Cytochrome P450: role in the metabolism and toxicology of drugs and other xenobiotics. Royal Society of Chemistry, Cambridge (UK), pp 354-383
129. Culm-Merdek KE, von Moltke LL, Gan L, Horan KA, Reynolds R, Harmatz JS, Court MH, Greenblatt DJ (2006) Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir. Clin Pharmacol Ther 79:243-254
130. Kroboth PD, McAuley JW, Kroboth FJ, Bertz RJ, Smith RB (1995) Triazolam pharmacokinetics after intravenous, oral and sublingual administration. J Clin Psychopharmacol 15:259-262
131. Greenblatt DJ, Wright CE, von Moltke LL, Harmatz JS, Ehrenberg BL, Harrel LM, Corbett K, Counihan M, Tobias S, Shader RI (1998) Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. Clin Pharmacol Ther 64:237-247
132. Varhe A, Olkkola KT, Neuvonen PJ (1994) Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 56:601-607
133. Greenblatt DJ, von Moltke LL, Harmatz JS, Counihan M, Graf JA, Durol ALB, Mertzanis P, Duan SX, Wright CE, Shader RI (1998) Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. Clin Pharmacol Ther 64:278-285
134. Warot D, Bergougnan L, Lamiable D, Berlin I, Bensimon G, Danjou P, Puech AJ (1987) Troleandomycin-triazolam interaction in healthy volunteers: pharmacokinetic and psychometric evaluation. Eur J Clin Pharmacol 32:389-393
135. Greenblatt DJ, von Moltke LL, Harmatz JS, Durol ALB, Daily JP, Graf JA, Mertzanis P, Hoffman JL, Shader RI (2000) Differential impairment of triazolam and zolpidem clearance by ritonavir. J Acquir Immune Defic Syndr 24:129-136
136. Villikka K, Kivistö KT, Backman JT, Olkkola KT, Neuvonen PJ (1997) Triazolam is ineffective in patients taking rifampin. Clin Pharmacol Ther 61:8-14
137. Greenblatt DJ, Divoll M, Abernethy DR, Moschitto LJ, Smith RB, Shader RI (1983) Reduced clearance of triazolam in old age: relation to antipyrine oxidizing capacity. Br J Clin Pharmacol 15:303-309
138. Greenblatt DJ, Harmatz JS, Shapiro L, Engelhardt N, Gouthro TA, Shader RI (1991) Sensitivity to triazolam in the elderly. N Engl J Med 324:1691-1698
139. Greenblatt DJ, Harmatz JS, von Moltke LL, Wright CE, Shader RI (2004) Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate. Clin Pharmacol Ther 76:467-479
140. Salvà P, Costa J (1995) Clinical pharmacokinetics and pharmacodynamics of zolpidem: therapeutic implications. Clin Pharmacokinet 29:142-153
141. Olubodun JO, Ochs HR, Trüten V, Klein A, von Moltke LL, Harmatz JS, Shader RI, Greenblatt DJ (2002) Zolpidem pharmacokinetic properties in young females: influence of smoking and oral contraceptive use. J Clin Pharmacol 42:1142-1146
142. Cysneiros RM, Farkas D, Harmatz JS, von Moltke LL, Greenblatt DJ (2007) Pharmacokinetic and pharmacodynamic interactions between zolpidem and caffeine. Clin Pharmacol Ther 82:54-62
143. Greenblatt DJ, Harmatz JS, von Moltke LL, Ehrenberg BL, Harrel L, Corbett K, Counihan M, Graf JA, Darwish M, Mertzanis P, Martin PT, Cevallos WH, Shader RI (1998) Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Clin Pharmacol Ther 64:553-561
144. Greenblatt DJ, Harmatz JS, von Moltke LL, Wright CE, Durol ALB, Harrel-Joseph LM, Shader RI (2000) Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. J Pharmacol Exp Ther 293:435-443
145. Lobo BL, Greene WL (1997) Zolpidem: distinct from triazolam? Ann Pharmacother 31:625-632
146. Nowell PD, Mazumdar S, Buysse DJ, Dew MA, Reynolds CF, Kupfer DJ (1997) Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. J Am Med Assoc 278:2170-2176
147. Dündar Y, Dodd S, Strobl J, Boland A, Dickson R, Walley T (2004) Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol 19:305-322
148. Berlin I, Warot D, Hergueta T, Molinier P, Bagot C, Peuch AJ (1993) Comparison of the effects of zolpidem and triazolam on memory functions, psychomotor performances, and postural sway in healthy subjects. J Clin Psychopharmacol 13:100-106
149. Rush CR, Griffiths RR (1996) Zolpidem, triazolam, and temazepam: behavioral and subjectrated effects in normal volunteers. J Clin Psychopharmacol 16:146-157
150. von Moltke LL, Greenblatt DJ, Granda BW, Duan SX, Grassi JM, Venkatakrishnan K, Harmatz JS, Shader RI (1999) Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. Br J Clin Pharmacol 48:89-97
151. Greenblatt DJ, von Moltke LL, Harmatz JS, Mertzanis P, Graf JA, Durol ALB, Counihan M, Roth-Schechter B, Shader RI (1998) Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. Clin Pharmacol Ther 64:661-671
152. Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT (2007) Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects. Br J Clin Pharmacol 63:116-120
153. Luurila H, Kivistö KT, Neuvonen PJ (1998) Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. Eur J Clin Pharmacol 54:336-340
154. Hesse LM, von Moltke LL, Greenblatt DJ (2003) Clinically important drug interactions with zopiclone, zolpidem and zaleplon. CNS Drugs 17:513-532
155. Olubodun JO, Ochs HR, von Moltke LL, Roubenoff R, Hesse LM, Harmatz JS, Shader RI, Greenblatt DJ (2003) Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. Br J Clin Pharmacol 56:297-304
156. Weinling E, McDougall S, Andre F, Bianchetti G, Dubruc C (2006) Pharmacokinetic profile of a new modified release formulation of zolpidem designed to improve sleep maintenance. Fundam Clin Pharmacol 20:397-403
157. Zammit G (2009) Comparative tolerability of newer agents for insomnia. Drug Saf 32:735-748
158. Greenblatt DJ, Legangneux E, Harmatz JS, Weinling E, Freeman J, Rice K, Zammit G (2006) Dynamics and kinetics of a modified-release formulation of zolpidem: comparison with immediate-release standard zolpidem and placebo. J Clin Pharmacol 46:1469-1480
159. Rosen AS, Fournié P, Darwish M, Danjou P, Troy SM (1999) Zaleplon pharmacokinetics and absolute bioavailability. Biopharm Drug Dispos 20:171-175
160. Fernandez C, Martin C, Gimenez F, Farinotti R (1995) Clinical pharmacokinetics of zopiclone. Clin Pharmacokinet 29:431-441
161. Fernandez C, Maradeix V, Gimenez F, Thuillier A, Farinotti R (1993) Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers. Drug Metab Dispos 21:1125-1128
162. Becquemont L, Mouajjah S, Escaffre O, Beaune P, Funck-Brentano C, Jaillon P (1999) Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism. Drug Metab Dispos 27:1068-1073